Media headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.0979712587106 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Separately, Evercore ISI assumed coverage on Madrigal Pharmaceuticals in a research note on Friday, September 22nd. They issued an “outperform” rating and a $65.00 price target for the company.

Shares of Madrigal Pharmaceuticals (MDGL) opened at 46.93 on Friday. Madrigal Pharmaceuticals has a 52 week low of $13.09 and a 52 week high of $49.48. The company has a 50-day moving average price of $25.32 and a 200-day moving average price of $18.05. The stock’s market cap is $586.39 million.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.09). Equities analysts anticipate that Madrigal Pharmaceuticals will post ($2.67) EPS for the current year.

In other news, Director Richard S. Levy bought 3,550 shares of the stock in a transaction on Monday, August 21st. The stock was acquired at an average cost of $15.88 per share, for a total transaction of $56,374.00. Following the acquisition, the director now owns 900 shares of the company’s stock, valued at $14,292. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard S. Levy bought 2,000 shares of the stock in a transaction on Wednesday, August 23rd. The stock was purchased at an average price of $16.12 per share, with a total value of $32,240.00. Following the completion of the acquisition, the director now directly owns 7,200 shares in the company, valued at approximately $116,064. The disclosure for this purchase can be found here. Insiders acquired a total of 9,100 shares of company stock valued at $145,840 over the last quarter. Company insiders own 66.40% of the company’s stock.

WARNING: “Madrigal Pharmaceuticals (MDGL) Receives News Sentiment Rating of 0.21” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/07/madrigal-pharmaceuticals-mdgl-receives-news-sentiment-rating-of-0-21.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Insider Buying and Selling by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.